The company’s LiquidBiopsy system developed for rare cell and cell-free isolation with downstream molecular characterization will be on display at booth #23123. In addition, research supporting serial monitoring of breast cancer via liquid biopsy testing will be published during the conference.
WESTLAKE VILLAGE, CA – June 1, 2017 – Cynvenio Biosystems, Inc. a leader in personalized medicine technology for cancer diagnostics, today announced that its LiquidBiopsy rare cell and cell-free isolation platform will be featured at the 2017 ASCO Annual Meeting at booth #23123. The event takes place June 2 - June 6, 2017, at McCormick Place in Chicago, IL. Also at the conference, study data collected via the LiquidBiopsy platform and supporting the utility of longitudinal monitoring of breast cancer patients will be published.
The LiquidBiopsy platform delivers a blood-to-sequence workflow that provides three DNA templates; a purified CTC pellet, a cfDNA sample, alongside a germline control. The CTC pellets sequence on less than 10ng of DNA input material, without the need for whole genome amplification, as opposed to other competing approaches which cannot match these specifications. When used with Cynvenio’s custom Next Generation Sequencing (NGS) gene panels and cloud-based bioinformatics, the LiquidBiopsy workflow can reduce processing times by 60%-80%. This means that labs can operate at higher scale, with better quality control, and more profitably by eliminating typical sequencing bottlenecks. At ASCO, the platform will be on display at the Thermo Fisher Scientific booth.
The results of two independent research studies will be presented at the conference in support of the utility of Cynvenio’s liquid biopsy approach for the serial monitoring of breast cancer patients. Both sets of research data were collected using Cynvenio’s LiquidBiopsy platform.
Cynvenio Poster Presentation:
Preliminary data collected from the first year of Cynvenio’s ongoing 211-patient TNBC research study (clinicaltrials.gov identifier NCT02639832) will be presented by Paul Y. Song, M.D., Chief Medical Officer of Cynvenio. The research supports the utility of longitudinal monitoring of triple negative breast cancer patients using Cynvenio’s ClearID liquid biopsy tests. The poster titled, “Use of serial multi-template liquid biopsies in triple negative breast cancer monitoring,” will be presented during the Breast Cancer—Metastatic session on Sunday, June 4, 8:00 AM to 11:30 AM in Hall A (Abstract #1091, Poster Board #83).
Research by Mount Sinai Medical Center, New York, NY:
Research by Cynvenio collaborator, Mount Sinai Medical Center, will be published in conjunction with the 2017 ASCO Annual Meeting with findings from a study of 20 patients diagnosed with stage I-IV breast cancer who received serial CTC/cfDNA liquid biopsy collections between October 2015 and November 2016. The study found that mutations were identified in 25% of patients, more frequently in cfDNA and not in every collected sample, supporting serial collection studies to monitor response. Presence of the same pathogenic mutations in the patient’s primary tumor suggests a role for surveillance in early stage, as well as advanced disease (Abstract #e23070).
About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit www.cynvenio.com, www.clearidmonitoring.com, and www.liquidbiopsy.com.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.